Stockwinners Market Radar for November 20, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EST Astellas Pharma, Welldoc enter into Digital Therapeutics alliance - Astellas Pharma and Welldoc announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar in Japan and certain other Asian markets for patients with diabetes, collaborate to broaden the adoption of BlueStar in the U.S. market, and jointly develop and commercialize digital therapeutics in other therapeutic areas globally.

18:58 EST Google to limit election ads audience targeting, will prohibit 'deep fakes' - Alphabet's Google said it is making a few changes to how it handles political ads on its platforms globally. "While we've never offered granular microtargeting of election ads, we believe there's more we can do to further promote increased visibility of election ads," the company said. "That's why we're limiting election ads audience targeting to the following general categories: age, gender, and general location (postal code level). Political advertisers can, of course, continue to do contextual targeting, such as serving ads to people reading or watching a story about, say, the economy. This will align our approach to election ads with long-established practices in media such as TV, radio, and print, and result in election ads being more widely seen and available for public discussion. (Of course, some media, like direct mail, continues to be targeted more granularly.) It will take some time to implement these changes, and we will begin enforcing the new approach in the U.K. within a week (ahead of the General Election), in the EU by the end of the year, and in the rest of the world starting on January 6, 2020." Google added that it is clarifying its ads policies and adding examples to show how its policies prohibit things like "deep fakes," misleading claims about the census process, and ads or destinations making demonstrably false claims that could significantly undermine participation or trust in an electoral or democratic process. "We want the ads we serve to be transparent and widely available so that many voices can debate issues openly," the company said. "We already offer election advertising transparency in India, in the EU, and for federal U.S. election ads. We provide both in-ad disclosures and a transparency report that shows the actual content of the ads themselves, who paid for them, how much they spent, how many people saw them, and how they were targeted. Starting on December 3, 2019, we're expanding the coverage of our election advertising transparency to include U.S. state-level candidates and officeholders, ballot measures, and ads that mention federal or state political parties, so that all of those ads will now be searchable and viewable as well." Reference Link

18:33 EST Tenet General Counsel sells 65K shares of common stock - In a regulatory filing, Tenet disclosed that its General Counsel Audrey Andrews sold 65.4K shares of common stock on November 18th. The total transaction size was $2M.

17:49 EST Therapix Biosciences to appeal Nasdaq delisting notice - Therapix Biosciences received a written Notice of Delisting from the Listing Qualifications Department of The Nasdaq Capital Market. The company intends to appeal this decision by requesting a hearing before a Nasdaq Hearings Panel to review Nasdaq's decision to delist the company. A hearing request by the company automatically stays the delisting of the company's securities pending issuance of the Panel's decision. On May 23, the company was advised that it no longer complied with the minimum $2.5M stockholders' equity requirement for continued listing on Nasdaq. On July 5, the company submitted to Nasdaq a plan to regain compliance with Nasdaq listing rules. Nasdaq granted an extension to enable the company to regain compliance with the Stockholders' Equity Requirement until November 18. The company did not regain compliance with the Stockholders' Equity Rule as a result of abandoning the proposed merger with Destiny Bioscience Global.

17:28 EST Raytheon awarded $386M Air Force contract modification - Raytheon has been awarded a $386M contract modification to the previously awarded contract for the total package approach, or TPA, to the Paveway family of weapons. The contract action provides a TPA for Paveway-specific activities including, but not limited to: studies, production, certification, integration and sustainment. This modification increases the ceiling of the indefinite-delivery/indefinite-quantity contract from the previously awarded amount of $110M to $496M. Work will be performed at Tucson, Arizona and Air Force test ranges. This modification involves 100% foreign military sales to countries with active cases to acquire Paveway weapon systems or have expressed interest in the Paveway family of weapons. The total cumulative face value of the contract is $496M. Foreign military sales funds are being used and no funds are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:08 EST Universal Corporation to acquire FruitSmart, terms not stated - Universal Corporation announced that it has entered into a definitive agreement to acquire FruitSmart, an independent specialty fruit and vegetable ingredient processor serving global markets. The business is headquartered in the Yakima Valley of the state of Washington, where it has approximately 200 employees and two manufacturing facilities. Universal Corporation expects the transaction to close in the current fiscal year. Following the close of the transaction, Terry Chambers, President of FruitSmart, will continue to lead the FruitSmart business as President. Universal Corporation anticipates this acquisition will be accretive to earnings the first fiscal year following closing. As previously outlined, Universal Corporation believes businesses in adjacent industries could represent at least 10% to 20% of earnings in the next five years. Universal Corporation expects to fund the transaction with a combination of cash on hand and existing borrowing capacity.

17:01 EST Kearny Financial raises quarterly dividend to 7c from 6c per share - Payable on December 20 to stockholders of record as of December 6.

16:46 EST L Brands backs FY19 free cash flow forecast at ~$750M - Cuts FY19 SSS view to "about flat to down slightly" from "up low single digits". Backs FY19 SG&A expense ratio of "about flat to 26.9% last year". Backs FY19 tax rate view of about 26%. Lowers FY19 CAPEX view to about $500M from $550M. Outlook taken from the company's investor slides accompanying Q3 earnings. Reference Link

16:40 EST Key Energy receives notice from NYSE regarding continued listing requirements - Key Energy Services announced that on November 18, 2019, the company received a letter from the New York Stock Exchange notifying it that, over a period of 30 consecutive trading days, the average closing price of Key's common shares was below the minimum $1.00 per share requirement for continued listing on the NYSE under Item 802.01C of the NYSE Listed Company Manual.

16:36 EST Markel executive chairman Alan Kirshner to retire - Markel Corporation announced that Alan I. Kirshner, the company's Executive Chairman and Chairman of the Board, informed the company that he will not stand for re-election at the company's 2020 Annual Meeting of Shareholders scheduled to be held May 11, 2020. Kirshner will retire as a director and officer of the company at the end of the meeting. Markel also announced that the Board of Directors selected current Board Member and Vice Chairman Steven A. Markel to succeed Kirshner as the next Chairman of the Board. The Board has named Alan to the honorary position of "Chairman Emeritus" of the Board upon retiring from his leadership positions in May of next year. "I'm grateful to have had the opportunity to serve as Chairman of Markel these last 33 years, working alongside terrific leaders and great employees, all of whom come to work each day determined to build one of the world's great companies," Kirshner said. "This coming year I'll celebrate both my 85th birthday and 60th anniversary at Markel, and believe these milestones mark the perfect time for me to retire from the Board and pass on the Chairman role to another proven leader, my good friend and long-time colleague, Steve Markel."

16:34 EST Cellectis wins patent challenge in Europe for CRISPR-Cas9 gene editing method - Cellectis announced that European Patent EP3004337, which claims a method of preparing T-cells for immunotherapy using the CRISPR-Cas9 system, initially granted on August 2, 2017, has been upheld by the European Patent Office following an opposition procedure initiated in May 2018. European Patent EP3004337 claims a method of genetically modifying T-cells by introduction into the cells and/or expression in the cells of an RNA-guided endonuclease, and a specific guide RNA that directs an endonuclease to at least one targeted locus in the T-cell genome, where it is expressed from transfected mRNA and guide RNA is expressed in the cells as a transcript from a DNA vector. The patent also covers the expansion phase of the resulting cells in vitro. The inventors of this patent are Dr. Andre Choulika, Chairman and CEO, Cellectis, Dr. Philippe Duchateau, Chief Scientific Officer, Cellectis and Dr. Laurent Poirot, VP, Immunology Department, Cellectis. To date, the upheld patent has a validity period extended to 2034.

16:34 EST Territorial Bancorp declares special dividend of 50c per share - Territorial Bancorp has declared a special cash dividend of 50c per share payable on December 18 to shareholders of record as of December 4. CEO Allan Kitagawa said, "As you know, we have had some one-time gains this year that put us ahead of the earnings we had for the first 3 quarters of 2018. We believe our capital levels are sufficient to permit us to declare our second special dividend for the year while still allowing us to execute our business plan. We will also continue our stock repurchase plan at a price that makes financial sense for our shareholders. Our Board of Directors will continue evaluating all avenues to enhance long-term shareholder returns. Including this special dividend and other dividends paid in 2019, stock purchased in our initial public offering at $10.00 per share will earn dividends equal to 14.9% of their initial investment in Territorial Bancorp."

16:33 EST L Brands reports Q3 SSS down 3% and comparable sales down 2% - Reports Q3: Victoria's Secret SSS down 8% and comparable sales down 7%; Bath & Body Works SSS up 9% and comparable sales up 5%.

16:32 EST Amerant completes acquisition of Mercantil Bank and Trust - Amerant Bancorp announced the completion of its previously announced acquisition of Grand Cayman-based Mercantil Bank and Trust Limited from Mercantil Holding Financiero Internacional , a former affiliate. The acquisition was approved by the Board of Governors of the Federal Reserve System and the Cayman Islands Monetary Authority. The Cayman Bank, which has approximately $195 million in assets under custody and management, is now wholly owned by Amerant Bank and has been rebranded "Elant Bank and Trust Ltd." The Cayman Bank serves and develops high net worth international customer relationships with offshore trust and estate planning services. The Company and its subsidiaries managed the Cayman Bank on behalf of Mercantil for approximately 30 years under service agreements. Amerant Bank and Amerant Trust will continue to manage the Cayman Bank. There are no integration risks or costs. "This acquisition continues to strengthen our ability to seamlessly offer customers specialized personal wealth management and private banking services to meet their evolving financial needs," said Millar Wilson, Vice-Chairman and CEO of Amerant. "It furthers the growth strategy for our wealth management business, and deepens and strengthens our international customer relationships."

16:31 EST Triumph Aviation Services Asia wins EASA design organization approval - Triumph Group announced that its Triumph Aviation Services Asia facility in Chonburi, Thailand recently received Design Organization Approval from the European Aviation Safety Agency Part 21J.574. The DOA approval allows the Triumph facility to design and validate nacelle components including thrust reversers, fan and inlet cowls. TASA is the first facility to receive a DOA in Thailand. "For an organization to be approved by EASA, it must first successfully demonstrate that it has in place robust processes, competency, and organizational structure needed to design and validate top quality aerospace component repairs," said Bill Kircher, Executive Vice President of Triumph Product Support. "There is a strong demand in the aerospace market for EASA DOA maintenance, repair and overhaul shops because their work adds significant value to the customers fleet of leased and owned aircraft."

16:28 EST La-Z-Boy boosts quarterly dividend by 8% to 14c per share - The board of directors declared a regular quarterly dividend of 14c per share, an increase of 8%, "demonstrating its confidence in our various growth strategies to further solidify our position in the marketplace and continue to deliver returns to shareholders," said the company's CEO.

16:20 EST Meta Financial announces new 7.5M share repurchase program - The company also announced on November 20 that its Board of Directors authorized a new share repurchase program to repurchase up to an additional 7,500,000 shares of Meta's common stock. The company repurchased all shares available for repurchase under the company's share repurchase plan previously announced on March 26. The new authorization will be effective November 21 through December 31, 2022. The company may repurchase shares on the open market and/or in privately negotiated transactions, which may include repurchases pursuant to Rule 10b5-1 trading plans, at times and prices considered appropriate, made from time to time at the discretion of the company, and subject to its assessment of alternative uses of capital, stock trading price, general market conditions and applicable regulatory and legal factors. The repurchase program does not obligate the Company to acquire any particular amount of common stock or to acquire shares on any particular timetable, and the program may be suspended at any time at the company's discretion.

16:18 EST PayPal to acquire Honey Science for approximately $4B - PayPal announced that it has agreed to acquire Honey Science Corporation, a rapidly-growing technology platform for shopping and rewards, for approximately $4B. Honey, in combination with PayPal's two-sided network, will transform the shopping experience for PayPal's consumers while increasing sales and customer engagement for its merchants. Founded in 2012, Honey is best known as a popular discovery tool that helps consumers find savings as they shop online. Following the acquisition, Honey will retain its headquarters and brand in Los Angeles, California. Honey co-founders George Ruan and Ryan Hudson will continue to lead the Honey team as part of PayPal's global consumer product and technology organization, reporting to Senior Vice President John Kunze. Honey was profitable on a net income basis in 2018. Subject to customary closing conditions, including the receipt of regulatory approvals, the transaction is expected to close in the first quarter of 2020. The acquisition is expected to be accretive to PayPal's non-GAAP earnings per share in 2021.

16:18 EST National Security Group announces stock buyback of up to $1M - The National Security Group announced that its board of directors has authorized a common stock repurchase program of up to $1M. Under the repurchase program, the company is authorized to repurchase shares in open market purchases as well as in privately negotiated transactions from time to time through May 31, 2020. Stock purchased under this program will be held as treasury stock and will be available for general corporate purposes.

16:17 EST Tecnoglass to delist from Colombia stock exchange - Tecnoglass announced that the company has commenced the process to delist its ordinary shares from the Colombia Stock Exchange, the "Bolsa de Valores de Colombia," upon which the shares listed on that exchange under the ticker symbol "TGLSC" will cease trading. The Colombia stock listing is secondary to Tecnoglass' primary listing on The Nasdaq Stock Market, which will serve as the exclusive exchange to transact Tecnoglass ordinary shares, upon completion of the delisting from the Colombia Stock Exchange. With over 99% of Tecnoglass shares traded on the NASDAQ over the past year, the delisting of secondary shares is expected to save on expenses, time and administrative resources associated with the Company's listing on a secondary exchange. The delisting of shares from the Colombia Stock Exchange is expected to be completed in Q3 of 2020, following approval by Tecnoglass shareholders and required regulatory approvals.

16:16 EST PayPal to acquire Honey Science for approximately $4B

16:15 EST ProPhase Labs announces special cash dividend of 25c per share - The dividend is payable on December 12, 2019 to stockholders of record as of December 3, 2019.

16:14 EST Tonix Pharmaceuticals to submit TNX-102 SL IND based on FDA feedback - Tonix Pharmaceuticals announced it has received the official meeting minutes from a recent Type B pre-IND meeting with the FDA. The FDA provided guidance and feedback supportive of Tonix's clinical development plans for TNX-102 SL as a potential treatment for alcohol use disorder, or AUD. Based on this feedback, Tonix plans to submit an IND application in Q1 of 2020 to support a Phase 2 proof-of-concept study.

16:12 EST Qiagen, LabCorp extend current Clinical Insights license with HGMD - Qiagen (QGEN) announced an agreement with LabCorp (LH) to extend their current QIAGEN Clinical Insights license with QIAGEN's Human Gene Mutation Database of human genetic variants, the world's largest database of inherited disease mutations. This agreement builds on the existing seven-year relationship between the two companies to develop, introduce and support new diagnostic tests. LabCorp will use HGMD across its network of laboratories to improve identification and interpretation of genetic variants within inherited diseases.

16:11 EST Neon Therapeutics announces corporate restructuring, to reduce workforce by 24% - Neon Therapeutics announced its new strategic focus on the development of its novel neoantigen-based T cell programs, in conjunction with a corporate restructuring. Neon will focus its efforts on the advancement of both personal and precision neoantigen-targeted T cell therapy candidates. Neon's most advanced program is NEO-PTC-01, its personal neoantigen-targeted T cell therapy candidate consisting of multiple T cell populations targeting the most therapeutically relevant neoantigens from each patient's tumor. Neon expects to file a clinical trial application, or CTA, in Europe by the end of 2019 to evaluate NEO-PTC-01 in patients with metastatic melanoma who are refractory to checkpoint inhibitors. NEO-PTC-01 leverages Neon's neoantigen platforms, including Recon, its machine-learning bioinformatics platform, and Neo-Stim, its proprietary process to directly prime, activate and expand neoantigen-targeting T cells ex vivo. Neon believes that this approach will allow NEO-PTC-01, a non-engineered product that leverages peripheral blood mononuclear cells, or PBMCs, as starting material, to specifically target each patient's individual tumor with T cells that can drive a robust and persistent anti-tumor response.The initial clinical development of NEO-PTC-01 will be focused on demonstrating monotherapy activity targeting metastatic solid tumors that are refractory to checkpoint inhibitor therapy. Following the planned submission of a CTA by the end of 2019, the company plans to initiate a Phase 1 dose escalation clinical trial in second-line metastatic melanoma in collaboration with the Netherlands Cancer Institute. The second planned indication for NEO-PTC-01 is second-line metastatic ovarian cancer, with potential to expand to other solid tumor types and potential development in the United States. As part of this new strategic focus, Neon is reducing its workforce by approximately 24% of its current headcount. At this time, Neon will cease undertaking new additional spending commitments related to its cancer vaccine programs, NEO-PV-01 and NEO-SV-01. The company will continue to conduct follow-up from its NT-002 clinical trial of NEO-PV-01 in first-line patients with untreated advanced or metastatic non-small cell lung cancer, with plans to report clinical data from this trial in Q3. Neon also plans to cease future enrollment in its NT-003 trial in metastatic melanoma. Neon believes these actions will improve its potential to bring value to patients, employees and shareholders. As part of these cost reduction efforts, Neon intends to explore strategic options. Neon expects that the restructuring and other cost-saving efforts will result in approximately $35M in annualized cost savings. Neon estimates that it will incur approximately $1.5M of pre-tax charges for severance and other costs related to the restructuring in 2019. With this restructuring, Neon now expects that its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into Q3. There can be no assurance that Neon's restructuring and other cost-saving efforts will be sufficient to continue the development of NEO-PTC-01 or its other programs through completion of the planned or ongoing clinical trials, nor that Neon's exploration of strategic alternatives will result in any transaction being entered into or consummated. Neon has not set a timetable for completion of this strategic review process and Neon does not intend to comment further unless or until its board of directors has approved a definitive course of action, the review process is concluded, or it determines that disclosure is required or appropriate.

16:09 EST Agilent raises quarterly dividend 10% to 18c per share - The dividend will be paid on Jan. 22, 2020 to all shareholders of record as of the close of business on Dec. 31, 2019.

16:07 EST Group 1 Automotive raises quarterly dividend to 29c from 28c per share - Payable on December 16 to stockholders of record as of December 2.

16:02 EST National Storage raises quarterly dividend to 33c from 32c per share - The dividend is payable on December 31, 2019 to shareholders of record on December 13, 2019.

15:30 EST Alnylam trading resumes

15:14 EST U.S. Senator Markey: Amazon Ring's policies 'open door' for privacy violations - US Senator Edward Markey disclosed the outcome of a months-long probe into Amazon's Ring camera-doorbells yesterday, "that reveal little to no privacy policies or civil rights protections for video collected by the technology. Senator Markey began his investigation in September of the internet-connected doorbell company Ring, which Amazon owns, and Ring's partnership with over 400 police departments. Reports indicate that the partnerships offered law enforcement officials access to video footage captured by Ring's products. New information also showed that Ring uses targeted language to encourage users to grant the police access to doorbell video footage, proactively courts law enforcement partners, and urges the police to take steps that will increase rates of video sharing. After two inquiries to the company, Senator Markey found an alarming disregard for basic privacy protections for consumers, as well as a lack of codified rules or policies to protect consumers from invasive or even discriminatory information-gathering practices."Connected doorbells are well on their way to becoming a mainstay of American households, and the lack of privacy and civil rights protections for innocent residents is nothing short of chilling," said Senator Markey. "Amazon Ring's policies are an open door for privacy and civil liberty violations. If you're an adult walking your dog or a child playing on the sidewalk, you shouldn't have to worry that Ring's products are amassing footage of you and that law enforcement may hold that footage indefinitely or share that footage with any third parties. Amazon's Ring is marketed to help keep families safe, but privacy rights are in real danger as a result of company policies. Amazon is not doing enough to ensure that its products and practices do not run afoul of our civil liberties." Reference Link

15:03 EST Arch Capital director John Vollaro sells over $406K in company shares - Arch Capital director John Vollaro disclosed in a filing that he had sold 9,900 shares of company stock at an average price of $41.02 per share on November 18. The total transaction value of the sale was $406,098.

14:50 EST Kazia Therapeutics up 63% as poster for SNO presentation circulated - Shares of Kazia Therapeutics are up $2.27, or 63%, to $5.87 in afternoon trading as a poster for a presentation being made at the Society for NeuroOncology meeting is being circulated among traders, according to contacts. The poster relates to the presentation of data from a Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O6-methylguanine-methyltransferase promoter status. Reference Link

14:32 EST Endo, Mallinckrodt sued by West Virginia AG over opioid crisis - West Virginia Attorney General Patrick Morrisey announced that he filed suit Tuesday against two opioid painkiller manufacturers, "continuing the office's battle against those who helped fuel the state's deadly drug epidemic." The lawsuits allege Endo Health Solutions (ENDP), Mallinckrodt (MNK) and various subsidiaries contributed to the opioid crisis by "individually engaging in strategic campaigns to deceive prescribers and misrepresent the risks and benefits of opioid painkillers," according to a press release from the AG's office. Reference Link

14:24 EST Alnylam announces framework for value-based agreements for Givlaari access - Alnylam Pharmaceuticals is announcing "a new and enhanced" framework for value-based agreements, or VBAs, designed to help patients with acute hepatic porphyria gain access to Givlaari injection for subcutaneous use. Approved today by the U.S. Food and Drug Administration, Givlaari is indicated for the treatment of adults with AHP. Alnylam is in active discussions with leading payers about VBAs for Givlaari and plans to incorporate this new ultra-rare disease framework into these discussions and negotiations. Alnylam has reached an agreement in principle with Harvard Pilgrim covering Givlaari, the company said. "Patients can sometimes experience lengthy delays waiting for access when a new medicine becomes available, as payers can be challenged to determine both which patients may best respond and the number of potentially undiagnosed patients in their plans. Our proactive approach with VBAs is intended to act as 'insurance for insurers' and builds upon our Alnylam Patient Access Philosophy to do everything we can to accelerate patient access to innovative medicines at a sustainable rate to the healthcare system. We are proud of the access achieved in the U.S. for Onpattro, and are committed to seeking innovative approaches for patient access with Givlaari and each of our approved medicines," added Barry Greene, President of Alnylam Pharmaceuticals.

14:05 EST Alnylam confirms FDA approval of Givlaari - Alnylam Pharmaceuticals announced that the FDA approved Givlaari injection for subcutaneous use for the treatment of adults with acute hepatic porphyria, or AHP. AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life. Givlaari was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home. Givlaari is expected to be available for shipment to healthcare providers in the U.S. by year-end.

13:44 EST Q BioMed jumps 500% after FDA approves making of non-opioid cancer drug - Earlier on Wednesday, BioMed announced FDA approval of its contract manufacturer IsoTherapeutics Group. ITG is now cleared to manufacture the company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. The long-awaited approval of the facility means that this important oncologic pain drug will soon be available to patients in the US and the rest of the world. Q BioMed is now the only FDA-approved source for this drug in the western world. The company is activating its planned commercial operations to support marketing, sales, and distribution in the US and, soon, in the rest of the world. Strontium-89 is an FDA-approved non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer. QBioMed CEO Denis Corin said, "We have been anticipating this critical regulatory step for a long time, certainly longer than we hoped, but we are thrilled that we can now move forward with certainty. This is the start of a new chapter in the evolution of our company, and we are looking forward to serving the needs of thousands of patients suffering from metastatic bone pain, providing them the chance to minimize their pain and positively impact life with metastatic disease. With millions of potential patients around the world, this is a major market opportunity for our company. In addition, we are investigating and planning expansion trials to provide additional indications for the drug and entry into an even larger therapeutic market." We look forward to updating our shareholders and those awaiting the drug availability in the next 60 days. Shares of Q BioMed are up around 500% or $1.80 per share to $2.16 per share in afternoon trading.

13:13 EST Apple partners with PlayNetwork to introduce 'Apple Music for Business' - The company said in a blog posting earlier: "Increase engagement with your brand with Apple Music for Business, brought to you by PlayNetwork. This revolutionary service combines world-class music curation, proprietary technology, and easy-to-use tools to let customers listen to, share, and enjoy the music your brand plays-no matter where they go." "Apple Music for Business solves for this, and breaks new ground for business music services by combining: An opportunity to work with music experts to develop the music identity of your brand and a custom sound that embodies it, drawing on incredible Apple Music playlists developed for every mood and genre. A technology platform built for your world, with intuitive interfaces and business-focused features which allows for different levels of corporate and store-level control. An integrated marketing program that helps you connect with customers through your existing channels, and extend your reach into new ones." Reference Link

13:08 EST General Motors confirms filing of RICO lawsuit against Fiat Chrysler Automobiles - General Motors (GM) announced the filing of a federal racketeering lawsuit against Fiat Chrysler Automobiles (FCAU) and former FCA executives who have pled guilty in an ongoing federal corruption probe. "The lawsuit exposes a multi-year pattern of corruption that FCA used to undermine the integrity of the collective bargaining process and cause GM substantial damages. At the core of this lawsuit are clear admissions of wrongdoing made by former FCA executives revealed through the continuing criminal investigation by the U.S. Attorney's Office in the Eastern District of Michigan. FCA was the clear sponsor of pervasive wrongdoing, paying millions of dollars in bribes to obtain benefits, concessions, and advantages in the negotiation, implementation, and administration of labor agreements over time. FCA corrupted the implementation of the 2009 collective bargaining agreement. It also corrupted the negotiation, implementation, and administration of the 2011 and 2015 agreements. FCA's manipulation of the collective bargaining process resulted in unfair labor costs and operational advantages, causing harm to GM. With this lawsuit, GM is seeking to reinforce that bargaining must be free from fraud and corruption. All damages recovered will be invested in the U.S. to benefit GM's employees and grow jobs," GM stated in its press release confirming earlier press reports of the lawsuit. "This lawsuit is intended to hold FCA accountable for the harm its actions have caused our company and to ensure a level playing field going forward," added Craig Glidden, GM Executive Vice President and General Counsel.

13:01 EST Cooper Tire appoints Ben Patel as Chief Technology Officer - Cooper Tire & Rubber Company named Ben Patel senior VP and Chief Technology Officer. In his new role, Patel is responsible for product planning and development, as well as engineering and technology across all regions. He leads a technology organization that includes a global technical center as well as technical centers in Asia, Europe and North America. Patel came to Cooper following eight years at Tenneco, where he most recently served as senior VP, Chief Technology Officer.

12:37 EST FDA approves Alnylam's Givlaari for acute hepatic porphyria - The Food and Drug Administration announced that it granted approval to Alnylam Pharmaceuticals' Givlaari for the treatment of adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme. "Prior to today's approval, treatment options have only provided partial relief from the intense unremitting pain that characterizes these attacks. The drug approved today can treat this disease by helping to reduce the number of attacks that disrupt the lives of patients," said Richard Pazdur, director of the FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research.

12:35 EST Pratt & Whitney GTF engines selected by GoAir to power 72 A320neo aircraft - Pratt & Whitney, a division of United Technologies Corp. (UTX), announced that GoAir has signed an agreement selecting the Pratt & Whitney GTF engine for the airline's order of 72 A320neo (EADSY) family aircraft. Pratt & Whitney will also provide GoAir with a long-term EngineWise Comprehensive service agreement. The aircraft are expected to begin delivery in 2021. "We are pleased to partner with Pratt & Whitney once again for our next batch of 72 Airbus A320neo aircraft. We believe that the Pratt & Whitney GTF fuel efficient engines are the best-in-class and most suited for our network and operations. With its revolutionary geared fan technology the GTF engines will allow GoAir to fulfill its commitment towards carbon emissions. These benefits result in quieter communities, quieter flights and cleaner air. Besides, the Pratt & Whitney GTF engines will permit GoAir to continue its aggressive growth strategy and at the same time maintain our cost advantage," said Jeh Wadia, Managing Director, GoAir. The Mumbai, India-based airline currently operates a fleet of 38 GTF-powered A320neo family aircraft.

12:26 EST Fiat Chrysler falls after GM alleges UAW bribes in new lawsuit - General Motors (GM) filed a lawsuit today in U.S. District Court in Detroit alleging Fiat Chrysler (FCAU) got an unfair business advantage by bribing officials of the United Auto Workers union, Tom Krisher of Associated Press reports. GM says Fiat was involved in racketeering by paying millions in bribes to get concessions and gain advantages in three labor agreements with the union, reports Krisher, citing the lawsuit. The suit alleges that Fiat corrupted the bargaining process with the UAW in the 2009, 2011 and 2015 union contracts to gain advantages over GM. Shares of Fiat Chrysler are down 2.5% to $15.20 following the AP's report while GM is down 2% to $35.56. Reference Link

11:52 EST Cigarette makers rising after FDA said to shelve nicotine cut plans - Shares of several makers of cigarette and tobacco products, including Altria Group (MO), British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM), are moving higher after Bloomberg reported that a FDA notice on its nicotine plan is no longer in the agency's regulatory agenda. Meanwhile, shares of 22nd Century (XXII), which has been developing a Very Low Nicotine Content cigarette, are down following news that the FDA is shelving a plan to require a sharp cut in nicotine in cigarettes.

11:39 EST Verizon and Respond unveil third 5G First Responder Lab cohort - Verizon, in partnership with Responder, unveiled the five companies that make up the third and final group of innovative startups for 2019 known as "Cohort 3" for the 5G First Responder Lab program at #OCR2019. Launched in November 2018, the 5G First Responder Lab is a first-of-its-kind innovation program that identifies promising technology companies from around the globe and gives them access to 5G technology to develop, test and refine their 5G solutions for public safety. The startups in Cohort 3 will focus on developing Artificial Intelligence for weapon detection, geo-intelligence, autonomous security and smart cities solutions, all powered by Verizon 5G Ultra Wideband. The startups participating in this cohort include: Edgybees: Augments live video feeds captured from any camera, human input or other data sources to provide clarity on operational environments Ekin: Developing revolutionary software and hardware with artificial intelligence to make modern cities safer and smarter, Knightscope: Developing autonomous security capabilities including self-driving technology, robotics and artificial intelligence Lumineye: Provides wall-penetrating radar sensing to help first responders identify people through walls, Zeroeyes: Developed a life-saving active shooter solution that uses Artificial Intelligence to actively monitor camera feeds to detect weapons. Reference Link

11:09 EST Amazon.com to create 500 jobs at new fulfillment center in Auburndale, Florida - Amazon announced plans to open a fulfillment center in Auburndale, Florida. When the site opens, Amazon will create more than 500 new, full-time jobs starting at $15 an hour with comprehensive benefits starting on day one. Employees at the more than one million-square-foot fulfillment center will pick, pack and ship large customer items, such as sports equipment, patio furniture, fishing rods, pet food, kayaks, bicycles, and larger household goods. Amazon currently employs more than 13,500 full-time associates throughout the state of Florida.

11:00 EST C&F Financial raises quarterly dividend 2.7% to 38c per share - The board of directors of C&F Financial Corporation has declared a regular cash dividend of 38c per share, which is payable January 1, 2020 to shareholders of record on December 13, 2019. This dividend represents a 2.7% increase over the prior quarter's dividend amount of 37c per share.

10:32 EST Milacron stockholders adopt merger agreement with Hillenbrand - Milacron Holdings (MCRN) announced that its stockholders voted to adopt the Agreement and Plan of Merger, dated as of July 12, 2019, among Milacron Holdings, Hillenbrand (HI) and Bengal Delaware Holding Corporation, at a special meeting of the Milacron stockholders held earlier today. Milacron's stockholders also approved the proposal to approve, on an advisory basis, specified compensation payable to Milacron's named executive officers in connection with the merger. The final voting results will be disclosed in a Current Report on Form 8-K, in accordance with the rules of the U.S. Securities and Exchange Commission. Milacron and Hillenbrand anticipate that the transaction will close on November 21, 2019.

10:03 EST Poly drops 3% to $25.02 after issuing guidance at investor day

10:00 EST Lowe's says expects FY19 adjusted operating margin up 40-60 basis points - Sees FY19: Cash flow of $4.5B, free cash flow approximately $3B, CapEx approximately $1.6B, $4B of share repurchases. Says: Feels "very good" about overall business trends in U.S... "Right on track" with business transformation process... Feels "very solid" about sales plans for Q4.

09:47 EST PagSeguro Digital falls -7.0% - PagSeguro Digital is down -7.0%, or -$2.56 to $34.20.

09:47 EST China Distance Education rises 10.8% - China Distance Education is up 10.8%, or 78c to $8.00.

09:47 EST California Resources rises 17.7% - California Resources is up 17.7%, or $1.10 to $7.30.

09:33 EST Aon plc to acquire CoverWallet, terms not disclosed - Aon announced that it has entered into a definitive agreement to acquire CoverWallet, a digital insurance platform for small and medium-sized businesses. Post-close, CoverWallet will join the growing portfolio of Aon's New Ventures Group, which functions as a growth-stage capability focused on delivering new sources of value to clients that expand Aon's addressable market. As part of the New Ventures Group portfolio, CoverWallet will apply its data and analytics capabilities, technology, and operational expertise to the broader Aon digital client experience, while also working closely with leadership across Aon's geographies and global solution lines to accelerate the growth of CoverWallet's core business. CoverWallet has more than 300 employees across engineering, digital marketing, data science, business intelligence, design, and operations, with offices in New York City, Rochester, NY, and Spain. Earlier this year, CoverWallet and Aon announced an initial commercial partnership, launched a pilot in Australia which later expanded to the U.S, and worked together to build additional pilot programs in the U.S. The transaction is expected to close during the first quarter of 2020, after which the CoverWallet organization will go to market as CoverWallet, an Aon company.

09:23 EST Diana Shipping announces direct continuation of contract for m/v Polymnia - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has agreed to extend the present time charter contract with Cargill International S.A., Geneva, for one of its Post-Panamax dry bulk vessels, the m/v Polymnia. The gross charter rate is $11,000 per day, minus a 4.75% commission paid to third parties, for a period of minimum eleven months to about thirteen months. The new charter period commenced on November 15, 2019. The "Polymnia" is a 98,704 dwt Post-Panamax dry bulk vessel built in 2012. This employment is anticipated to generate approximately $3.63M of gross revenue for the minimum scheduled period of the time charter.

09:06 EST Scorpio Tankers announces purchase of call options by company president - Last night, Scorpio Tankers announced that the President of the company, Robert Bugbee, has purchased call options on 200,000 common shares, or 2,000 call option contracts, of the company with strike price of $32.00 and an expiration of January 2020 for the consideration of $450,000.

09:04 EST Tandem Diabetes announces Health Canada approval of t:slim X2 pump - Tandem Diabetes announced Health Canada approval of the t:slim X2 insulin pump with Basal-IQ technology. Basal-IQ technology, a predictive low-glucose suspend, or PLGS, algorithm, utilizes sensor values from an integrated Dexcom G6 continuous glucose monitor, or CGM, to help reduce the frequency and duration of low-glucose events. All in-warranty t:slim X2 pump users in Canada will have the option to add Basal-IQ technology to their existing pump free of charge via remote software update in February 2020. Tandem expects to begin shipping t:slim X2 pumps with Basal-IQ technology to new customers in the first quarter of 2020.

09:03 EST Bank First National to acquire Timberwood Bank - Bank First signed an agreement and plan of merger with Tomah Bancshares, parent company of Timberwood Bank, a Wisconsin state-chartered bank, under which Timberwood Bank will merge into Bank First in an all-stock transaction. Each Timberwood Bank shareholder will receive 5.1445 shares of BFC common stock for each share of Timberwood Bank common stock they own. The aggregate consideration was originally modeled at approximately $32.6M but will fluctuate based on the per share valuation of Bank First common stock on the closing date. As of September 30, Timberwood Bank had approximately $193M in consolidated assets, $127M in net loans, $155M in consolidated deposits and $20M in consolidated shareholders' equity. Based on the financial results as of September 30, the combined company will have total assets of approximately $2.4B, net loans of approximately $1.8B and deposits of approximately $2.0B. The Agreement has been approved by the Boards of Directors of Bank First and Timberwood Bank. The closing of the transaction, which is anticipated to take place in the spring of 2020, is subject to customary conditions, including regulatory approval and approval by Timberwood Bank shareholders.

09:00 EST Fly Intel: Pre-market Movers - HIGHER: Aravive (ARAV), up 220% after announcing new data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response, the company said... Endo (ENDP), up 4% after announcing that the FDA has accepted for review the original biologics license application for collagenase clostridium histolyticum. UP AFTER EARNINGS: Target (TGT), up 10%... Lowe's (LOW), up 5%... Qiwi (QIWI), up 3%. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 15%... PagSeguro Digital (PAGS), down 5%... Pinduoduo (PDD), down 22%... Avaya (AVYA), down 3%. LOWER: Quidian (QD), down 3% after Macquarie analyst Dexter Hsu downgraded shares to Underperform from Neutral with a price target of $4, down from $7. The analyst sees increasing risks from asset quality and regulation.

08:47 EST Neptune Wellness and Canopy Growth amend processing volume agreement - Neptune Wellness (NEPT) has entered into an amended and restated processing agreement with Canopy Growth (CGC). The parties have agreed to an amended schedule of processing volumes committed to Neptune by Canopy. In addition, the parties agreed to remove certain preferential rights previously granted to Canopy with respect to Neptune's capacity and pricing. Effective June 30, 2020, volume and pricing will be negotiated between the two parties based on market conditions. The 3-year term of the agreement remains unchanged and expires on June 30, 2022. As a result of the revised terms, Neptune expects to reduce its client concentration risk and diversify its customer base.

08:35 EST Predictive Oncology secures $15M equity line - Predictive Oncology announced that it entered into a $15M common stock purchase and registration rights agreement with Oasis Capital to purchase from the Company up to Fifteen Million Dollars of the Company's Common Stock. Under the purchase agreement, Predictive Oncology has the right to sell up to $15M of its stock to Oasis Capital over a 36-month period, upon satisfaction of the conditions in the purchase agreement including the effectiveness of a resale registration statement which has occurred. Predictive Oncology will control the timing and amount of any sales to Oasis Capital, and Oasis Capital is obligated to make purchases in accordance with the purchase agreement. The equity purchase agreement allows the Company to fund its needs in a more expedient and cost-effective manner. The equity line is designed to provide a capital runway and to take advantage of the milestones to advance CancerQuest 2020.

08:32 EST Couche-Tard extends ATM partnership with Cardtronics - Couche-Tard has selected Cardtronics to own and operate ATMs in the company's stores throughout the continental United States. The agreement extends and expands the long-term partnership between Cardtronics and Couche-Tard, and covers store banners including Circle K, Corner Store, Flash Foods and The Pantry.

08:20 EST Agraflora enters into supply agreement with Red Phoenix International Trading - AgraFlora Organics International announced the Company has entered into a preferred supply agreement with Canadian consumer packaged goods broker and wholesaler, Red Phoenix International Trading. Under the terms of the Supply Agreement, RPI will distribute AgraFlora's portfolio of organic cannabis sativa seed oil infused CPGs, including its Whole Hemp Health organic lip balm, as well as its Edibles & Infusions hemp-derived gummy stock-keeping units to domestic big box food retailers. RPI boasts wholesale distribution agreements with the following Tier 1 Canadian food retailers: Loblaws Inc.; Metro Inc.; Sobeys Inc.; The North West Company; and, Giant Tiger Stores Ltd. The Company forecasts its Supply Agreement with RPI will accelerate its stock turn and sell-through metrics of associated organic cannabis sativa seed oil infused CPGs by a factor of three. Additionally, the Supply Agreement will augment AgraFlora's pursuit to secure a critical mass of high visibility shelf space, whilst familiarizing consumers with its premium suite of cannabis 2.0 SKUs.

08:15 EST Heat Biologics presents additional Phase 2 data from Cohort A of HS-110 trial - Heat Biologics presented additional Phase 2 interim top line data from Cohort A of the company's Phase 2 trial of its T-cell activating cell-based therapy, HS-110, in combination with Opdivo in advanced non-small cell lung cancer, or NSCLC, at a poster session at the American Association for Cancer Research, or AACR. Cohort A enrolled only previously treated patients who have never received a checkpoint inhibitor, or CPI. The company reported median overall survival, or mOS, of 16.9 months with 50% of patients censored with median follow up of 17 months. This compares favorably to the 12.2 months mOS reported in the Checkmate 057 study with nivolumab alone in a similar patient population. The company also reported an objective response rate, or ORR, per iRECIST of 22%, and a disease control rate, or DCR, of 48%, with tumor shrinkage observed in 46% of patients. Moreover, mOS of patients experiencing dermal injection site reactions, or ISR, was 42.1 months. Statistically significant improvement in progression-free survival, or PFS, and mOS was observed compared to those without ISR. Median overall survival was 16.9 months.Median overall survival of ISR positive patients was 42.1 months vs. an ISR negative mOS of 5.9 months. A prospectively defined analysis of PD-L1 negative vs. PD-L1 positive showed a difference in mOS of 16.9 months to 42.1 months, respectively. Objective Response Rate by iRECIST was 22% and DCR of 48%. There was tumor shrinkage in 46% of patients. Patients who achieved stable disease or better showed statistically significant decreases in peripheral blood T cell subsets from baseline while on combination treatment.

08:10 EST Axcella announces issuance of U.S. Patent covering EMM compositions - Axcella Health announced the issuance of U.S. Patent 10,471,034. This is the third EMM-related patent that Axcella has received to date, and it covers an array of EMM compositions, including AXA1125 and AXA1957, the company's product candidates for non-alcoholic steatohepatitis, or NASH. Issued earlier this month, Patent 10,471,034 broadens the coverage for composition of matter claims, independent of use.

08:08 EST Amazon announces plan to open a fulfillment center in Auburndale, Florida - Amazon announced plans to open a fulfillment center in Auburndale, Florida. When the site opens, Amazon will create more than 500 new, full-time jobs starting at $15 an hour with benefits starting on day one. Employees at the more than one million-square-foot fulfillment center will pick, pack and ship large customer items, such as sports equipment, patio furniture, fishing rods, pet food, kayaks, bicycles and larger household goods. Amazon currently employs more than 13,500 full-time associates throughout the state of Florida.

08:06 EST Booz Allen, Medallia form strategic alliance - Medallia (MDLA) announced a strategic partnership with Booz Allen Hamilton (BAH) that fuses Booz Allen's Experience Management consulting expertise and implementation services with Medallia's award-winning Customer Experience Management platform, the Medallia Experience Cloud. This new partnership is designed to enable government agencies to deliver world-class customer experience, or CX, and employee experience programs that are powered by Medallia and informed, designed and delivered by Booz Allen, to empower those in public service to collect, analyze, and act on feedback directly from those they serve. "The strategic partnership with Medallia will take Booz Allen's CX capability and build that expertise within the Medallia Experience Cloud platform to deliver experience management programs tailored to the public sector."

08:05 EST ManTech wins $177M in health awards - ManTech announced that it has advanced its position in the Federal Civilian healthcare services arena with a trio of awards totaling $177M. The three awards: Navy and Marine Corps Public Health Center: With this five-year $84M task order, ManTech will maximize readiness through force health protection strategies and solutions for public health threats. ManTech will provide analytic-based metrics that support the full range of customer healthcare and scientific programs, measuring the impact of vulnerabilities, assessing potential outcomes, and recommending specific actions that optimize warfighter performance, readiness, lethality and survivability. Defense Health Agency Medical Logistics: Through this five-year $59.4M task order by the Defense Health Agency, ManTech will support the Defense Medical Logistics - Enterprise Solution, an acquisition program that provides vital supply chain management support for cost-effective, state-of-the-art healthcare delivery to active duty and reserve members of the U.S. military and their families. ManTech will support the technical refresh of DML-ES, enhancing operations and maintenance, expanding the adoption of logistics systems at VA treatment facilities, providing end-to-end cybersecurity, and facilitating cost-effectiveness and performance gains via cloud migration. Defense Health Agency IT Infrastructure: Under this one-year $33.5M task order by the Defense Health Agency, ManTech will support the Desktop to Data Center Program Executive Office, implementing a standard baseline platform and improving network infrastructure.

08:02 EST AbbVie, Dragonfly Therapeutics announce multi-target research collaboration - Dragonfly Therapeutics and AbbVie announced a multi-target research collaboration designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for autoimmune and oncology indications. The collaboration grants AbbVie the option to license exclusive worldwide intellectual property rights to develop and commercialize products directed to specific targets developed using Dragonfly's TriNKET technology platform. AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties.

07:54 EST Novo Nordisk says on track to meet current long-term financial targets - Novo Nordisk announced it is hosting a Capital Markets Day where the company is introducing its strategic aspirations. "Based on the latest financial guidance provided in connection with the financial report for the first nine months of 2019, Novo Nordisk is on track to meet its current long-term financial targets comprising average operating profit growth of 5%, cash-to-earnings of 85% - 3-year average - and operating profit after tax over net operating assets of 80%." To reflect the broad growth aspects of Novo Nordisk across therapy areas and geographies, the current approach to long-term financial targets focusing on specific financial aspects is no longer sufficiently describing Novo Nordisk's future growth outlook. Consequently, Novo Nordisk is replacing the current long-term financial targets structure with a more comprehensive approach describing the future growth aspirations of the company under the headline: strategic aspirations for 2025. The strategic aspirations reflecting the sustained growth opportunities until 2025 are intended to cover future growth drivers of Novo Nordisk and thereby providing investors with an understanding of Novo Nordisk's growth and investment opportunities across therapy areas and geographies, the company stated. "Novo Nordisk is on track to meet its current long-term financial targets, and we have therefore decided to introduce our new strategic aspirations covering the future growth opportunitiesWe believe the future growth opportunities for Novo Nordisk are very promising and with the introduction of the strategic aspirations, we are now providing a more comprehensive approach to describe our growth drivers," said Lars Fruergaard Jorgensen, CEO of Novo Nordisk.

07:50 EST Exelon begins to acquire full ownership of three nuclear energy facilities - Exelon announced that EDF is exercising the put option to sell its 49.99% interest in the R.E. Ginna, Nine Mile Point and Calvert Cliffs nuclear energy facilities. As Exelon has reported in its financial filings, the put option was established in connection with the joint operating services agreement signed by the two companies in April 2014 to enable Exelon Generation to take over operations at the three nuclear plants. Exelon Generation already is the majority owner and operator of the plants, which are located in New York and Maryland. Exelon Generation's purchase of EDF's ownership interest will have no impact on plant operations or employees. As part of the acquisition process, EDF and Exelon Generation will seek a negotiated agreement on the sale price. If an agreement cannot be reached, the price will be set through a third-party arbitration process to determine fair market value. The transaction will require approval by the New York Public Service Commission, the Federal Energy Regulatory Commission and the Nuclear Regulatory Commission. The process and regulatory approvals could take one to two years or more to complete. Exelon Generation would become the full 100% owner of the three zero-carbon nuclear energy facilities, which consist of the single-unit R.E. Ginna Nuclear Power Plant and the dual-unit Nine Mile Point Nuclear Station, both in upstate New York; and the dual-unit Calvert Cliffs Nuclear Power Plant in Maryland.

07:37 EST Hologic to sell its Cynosure business for $205M, to enter new $205M ASR - Hologic announced that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205M in cash, subject to certain closing adjustments. Net of these adjustments, Hologic expects net cash proceeds of approximately $138M. Under the terms of the agreement, approximately 825 employees will transfer with the Cynosure business. The transaction is expected to close around the end of calendar 2019, subject to regulatory approvals and other customary conditions. Hologic also announced that it intends to enter into an accelerated share repurchase, or ASR, program to buy back $205M of the company's common stock. The ASR will be completed pursuant to a new $205M share repurchase authorization that has been approved by Hologic's board of directors. This is in addition to the company's current share repurchase authorization, under which $211M remained on September 28. Because Hologic began the process of divesting Cynosure before its fiscal year-end, but completed negotiations after releasing its most recent quarterly results, the transaction is expected to result in a significant additional non-cash impairment charge that will be recorded in Hologic's GAAP results for Q4. The company expects to record an additional pre-tax impairment charge estimated in the range of $155M-$185M in Q4 to reduce the carrying value of the asset group to its fair value. In Q1 of FY20, this asset group will meet the criteria for assets held-for sale and will be recorded at fair value less costs to sell, which could result in additional charges. Going forward, the divestiture is expected to have an immaterial impact on Hologic's revenue growth rate, while increasing non-GAAP gross and operating margin as a percentage of revenue. In FY20, the divestiture and the ASR together are forecast to increase Hologic's diluted EPS by approximately 2c on both a GAAP and non-GAAP basis. Hologic expects to provide a full update to its financial guidance for FY20 when it reports its first-quarter results. In addition, the loss resulting from the divestiture is expected to contribute to a U.S. cash tax refund of at least $300M to be received during calendar 2022.

07:35 EST A.H. Belo announces restatement, receives NYSE notice on late 10-Q filing - A. H. Belo Corporation announced in a Form 8-K filed with the Securities and Exchange Commission that it will not timely file its quarterly report on Form 10-Q for the quarter ended September 30, 2019, and has determined to restate its 2018 audited financial statements. The restatement will impact three areas of the 2018 audited financial statements: impairment of goodwill and long-lived assets, the income tax valuation allowance, and management's report on internal control over financial reporting and evaluation of disclosure control procedures included in Item 9A of the 2018 Form 10-K. The asset impairment and valuation allowance are due to a re-evaluation of the timing of the Company's impairment of assets related to its marketing services segment and consequent calculation of its tax valuation allowance, both of which are non-cash items. The Company's independent public accounting firm, Grant Thornton LLP, selected the Company's 2018 audit for internal review by its risk and quality control group in August. The Public Company Accounting Oversight Board subsequently selected Grant Thornton's audit of the Company's 2018 audited financial statements for review. Due to the Company's delay in filing its quarterly report on Form 10-Q for the third quarter, it received a notice today from the New York Stock Exchange stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual. In accordance with NYSE rules, the Company contacted the NYSE to discuss the status of the late filing. The noncompliance with the timely filing criteria under the NYSE Listed Company Manual has no immediate effect on the listing or trading of the Company's common stock on the NYSE. The NYSE has informed the Company that, under NYSE rules, the Company will have six months from the Form 10-Q due date to file the Form 10-Q with the SEC. The Company regains compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-Q with the SEC.

07:33 EST VIVUS announces results of clinical study of Qysmia in patients with BED, BN - VIVUS announced the results of a clinical study demonstrating that patients with binge-eating disorder or bulimia nervosa receiving Qsymia capsules CIV had a significant reduction in binge day frequency compared with placebo over four weeks. Additionally, Qsymia was well tolerated in these patient populations. The study results appear online in the International Journal of Eating Disorders. The randomized, double blind, placebo-controlled, crossover study enrolled 22 patients who were randomized to Qsymia or placebo for 12 weeks. The mean baseline body mass index for the 22 was 31.1 kg/m2. Following a two-week washout, patients crossed over to the other arm for 12 weeks. The primary outcome was the number of objective binge-eating days over four weeks; secondary outcomes included binge abstinence. Demographics, vital signs, eating disorder behaviors, mood and side effect data were also collected. Key findings from the study include: Mean OBE days over four weeks was 16.2 at baseline and decreased to 4.2 days and 13.2 days following Qsymia treatment and placebo, respectively. Abstinence rates were 63.6% with Qsymia and 9.1% with placebo. Qsymia was associated with a mean decrease in weight of 5.8 kg, compared with a mean gain of 0.4 kg on placebo. There was a significant improvement in secondary measures assessing eating disordered related pathologies and comorbid mood symptoms and marked improvements in depressive symptoms were also observed in patients receiving Qsymia compared to placebo. No serious adverse events were reported. Patient-reported adverse events while on Qsymia were dry mouth, insomnia, paresthesia, dysgeusia, anxiety, nausea, cold intolerance, decreased appetite, dizziness, fatigue, hair loss and difficulty finding words. Dropout rates were the same between the Qsymia and placebo groups. Blood pressure and heart rate changes with Qsymia were minimal and similar to placebo. Responses were not significantly different for BED versus BN. Binge eating returned and abstinence rates decreased during the eight-week post-treatment follow-up period, suggesting that additional approaches to improved maintenance are needed

07:31 EST MYOS' Fortetropin shows muscle increase in accepted clinical trial presentation - MYOS RENS, owner of Fortetropin, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced that an abstract based on the results from a clinical trial evaluating the impact of Fortetropin on the rate of muscle protein synthesis in older men and women has been accepted for an oral presentation at the upcoming International Conference on Frailty and Sarcopenia Research that will take place in Toulouse on March 11, 2020. In this clinical study, 20 subjects consumed either Fortetropin or a macronutrient-matched placebo for 21 days. For subjects who received Fortetropin, the average muscle protein synthesis rate was significantly higher compared to the placebo group. Fortetropin was shown to increase the average muscle protein synthesis rate, providing the potential to improve muscle health among older adults.

07:27 EST Rockwell Automation, Ansys announce strategic partnership - Rockwell Automation (ROK) and Ansys (ANSS) provided the following announcement: "Industrial companies now have access to a streamlined, holistic, end-to-end solution for design, automation, production and lifecycle management, thanks to a new strategic partnership between Rockwell Automation and ANSYS. The partnership between Rockwell Automation, the world's largest company dedicated exclusively to industrial automation and information, and ANSYS, the industry leader in simulation software, was announced at Rockwell Automation's 28th annual Automation Fair in Chicago. ANSYS and Rockwell Automation will help customers design simulation-based digital twins of products, processes or manufacturing. Historically manufacturers would dedicate an unimaginable amount of time and money to develop and test physical product prototypes. Now customers can design and test through simulation to accelerate development and analysis, improving product quality and reducing testing time across their organization."

07:24 EST ACI Worldwide sees FY20 adjusted EBITDA of $425M-$445M - This range compares to FY19 projections of $360M-$380M. As part of its Analyst Day presentation yesterday, the company offers the following 5-year targets: Organic revenue growth in mid-to-upper single digits, adjusted EBITDA margin expansion of 100bps per year, and operating free cash flow tracking adjusted EBITDA growth. Reference Link

07:21 EST Wingstop expands international footprint to France - Brescia Investissement SAS, a brand partner of Wingstop, opened the doors to Wingstop's first France location in Toulon at 28 Avenue Ste Claire, 83160 La Valette-du-Var. Brescia plans to open 75 Wingstops in France by 2029. The expansion into France marks Wingstop's ninth country outside of the U.S.

07:16 EST Apple announces construction of new campus in Austin, TX - Apple announced the start of construction on its new campus in Austin, Texas, as part of its broad expansion in the city. At a production facility just a short distance away, Apple is preparing to ship the all-new Mac Pro to customers starting in December. "Building the Mac Pro, Apple's most powerful device ever, in Austin is both a point of pride and a testament to the enduring power of American ingenuity," said Tim Cook, Apple's CEO. "With the construction of our new campus in Austin now underway, Apple is deepening our close bond with the city and the talented and diverse workforce that calls it home. Responsible for 2.4 million American jobs and counting, Apple is eager to write our next chapter here and to keep contributing to America's innovation story." The all-new Mac Pro was unveiled at Apple's annual Worldwide Developer Conference in June. Mac Pro units are now in production in Austin and will soon ship to customers across the Americas. "The 244,000-square-foot Mac Pro facility employs more than 500 people in a range of roles, including electrical engineers and electronics assemblers, who build each unique unit to customers' specifications. Apple's growth in Austin is part of the company's nationwide expansion - announced in January 2018 - to increase its investment in manufacturing, engineering and other jobs across the US. Apple is on track to contribute $350 billion to the US economy between 2018 and 2023, and during that time will hire an additional 20,000 employees in cities across the country."

07:12 EST Emerald Health Therapeutics calls Village Farms allegations 'inaccurate' - Emerald Health Therapeutics (EMHTF) responded to "inaccurate allegations" made by Village Farms International (VFF) in connection with their 50/50 joint venture, Pure Sunfarms Corp. and updated the market on certain related matters. The company said, "Late yesterday evening Emerald received notice from Village Farms stating that Village Farms had advanced $5.94M to PSF for additional equity. Village Farms claims that it has the right to acquire these shares under the PSF shareholders' agreement. In fact, Village Farms has no such right. Despite Village Farms' claims, Emerald continues to hold a full 50% ownership interest in PSF." "We were shocked to receive this notice," said Riaz Bandali, President and CEO of Emerald. "We can't speculate on Village Farms' motivation for making this irresponsible and inaccurate claim, but we want to reassure investors that there has been no change in ownership of PSF. We are disappointed at the aggressive approach of Village Farms in this matter; however, we continue to believe that cooler heads will prevail. Until then we will assertively defend our rights on behalf of our shareholders in the face of these unwarranted actions by Village Farms." The company said, "Under the PSF shareholders' agreement, Village Farms only has the right to make an equity contribution and increase its ownership stake if the other shareholder has defaulted under a contribution notice. A contribution notice can only be issued in certain specific circumstances and no such contribution notice was issued by PSF. The disclosure of Village Farms relating to this issue is therefore incorrect. Emerald has acted in good faith with respect to its Pure Sunfarms joint venture, to date contributing over $37.4M in equity investment in the D3 & D2 greenhouse operations, providing $13M in an interest bearing loan, and purchasing over $20.5M of cannabis as per the terms of its supply agreement with PSF."

07:07 EST Leidos teams up with Pharicode on NEST contract to provide IT services to NASA - Pharicode teamed with Leidos on their awarded NASA end-user services and technologies, or NEST, contract to provide information technology, or IT, end-user services. Under the single-award, firm-fixed priced, work will be performed at 10 NASA centers nationwide. The $2.9B NEST contract will be managed by the End-User Services Program Office at the Marshall Space Flight Center in Huntsville, Alabama. Pharicode is also headquartered in Huntsville, Alabama. The NEST contract establishes a long-term outsourcing arrangement to provide and manage most of NASA's personal computing hardware, supporting infrastructure, agency standard software, mobile IT services, help-desk support, and other associated end-user services. Under the contract, Pharicode will provide ServiceNow implementation services, Microsoft administration and infrastructure services, and managed support services.

07:07 EST Rockwell Automation, Ansys announce strategic partnership - Industrial companies now have access to a streamlined, holistic, end-to-end solution for design, automation, production and lifecycle management, thanks to a new strategic partnership between Rockwell Automation (ROK) and ANSYS (ANSS). Rockwell Automation and ANSYS announced the partnership at Rockwell Automation's 28th annual Automation Fair in Chicago. ANSYS and Rockwell Automation will help customers develop simulation-based digital twins of products, processes or manufacturing. Historically manufacturers would dedicate an unimaginable amount of time and money to develop and test physical product prototypes. Now customers can design and test through simulation to accelerate development and analysis, improving product quality and reducing testing time across their organization.

07:05 EST Aurora Cannabis names Dr. Shane Morris CPO and Andre Jerome CIO - Aurora Cannabis is pleased to announce that effective immediately, Dr. Shane Morris, formerly Senior Vice President of Product Development and Regulatory Affairs, has been promoted to Chief Product Officer, and Andre Jerome, formerly Senior Vice President of Business Integrations, has been promoted to Chief Integration Officer.

07:03 EST Aravive reports data from ongoing Phase 1b portion of AVB-500 trial - Aravive announced new data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival. PFS is the primary endpoint for platinum-resistant ovarian cancer clinical trials. At the 10 mg/kg dose, patients that met or exceeded the minimal efficacious concentration of AVB-500 demonstrated a greater than four-fold increase in median PFS over those with low exposure and approximately two-fold improvement in overall response rate, including one complete response. Patients who achieved sufficient AVB-500 exposure also showed improvements in duration of response and clinical benefit rate, with reduced chance of progressing by 3.2-fold. The open-label, Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 enrolled patients with platinum-resistant recurrent ovarian cancer in two cohorts, one investigating a combination of AVB-500 with pegylated liposomal doxorubicin and the other a combination with paclitaxel. All patients were treated with 10mg/kg AVB-500 every other week. The company previously reported drug exposure-response relationship among the initial patients receiving 10 mg/kg. The study identified a minimal efficacious concentration that is consistent with at least 95% target engagement based on independent pharmacokinetic modeling. At the 10 mg/kg dose, 17 of 31 patients in the study achieved the minimal efficacious concentration after the first dose of AVB-500. The baseline characteristics, demographics and safety parameters were comparable between patients who achieved the minimal efficacious concentration and those who fell below that threshold. The analysis shows that the clinical benefit at this dose level in the study can be primarily attributed to AVB-500 exposure. Other notable findings: The patient with CR that is pending confirmation achieved the MEC of AVB-500 and was on paclitaxel. She had a baseline serum GAS6 level typical of the platinum-resistant ovarian cancer population and two-fold higher than that observed in healthy volunteers. She also exhibited poor prognostic factors, including two prior lines of therapy and platinum-free interval of less than three months. Among the patients who responded to AVB-500, four of seven remain responders and continue on study, and two patients remain on AVB-500 as a single agent. All four patients achieved the minimal efficacious AVB-500 concentration. Among the 13 patients whose best response was SD, four achieved the MEC of AVB-500 and remain on study. One SD patient, whose trough level was below the minimal efficacious concentration, did not progress but withdrew consent. Because the study is still ongoing and includes only patients above the MEC, duration of response and PFS may continue to evolve. These data confirm the company's strategy to investigate higher doses in the current Phase 1b study, to determine if a greater proportion of patients can exceed the MEC. According to our modeling, a dose of 20 mg/kg should allow greater than 90% of the patients to achieve the MEC. It is anticipated 6 to 12 patients will be treated with 15mg/kg and an additional 12 patients will be treated with 20mg/kg. An independent safety monitoring group will review data from the 15mg/kg group prior to escalation to the 20mg/kg dose. AVB-500 continues to be well-tolerated and there have been no serious and unexpected adverse reactions or dose-limiting toxicities to date.

07:02 EST Broadridge acquires ClearStructure Financial Technology, terms not disclosed - Broadridge Financial Solutions has acquired ClearStructure Financial Technology, a global provider of portfolio management solutions for the private debt markets. Jefferies acted as the exclusive financial advisor to Broadridge. Marlin & Associates acted as the exclusive strategic and financial advisor to ClearStructure Financial Technology. Terms of the transaction were not disclosed.

06:55 EST CrossAmerica comments on sale of company interests by Alimentation Couche-Tard - CrossAmerica and Alimentation Couche-Tard announced that Couche-Tard has sold all of its ownership interest in CrossAmerica to investment vehicles controlled by Joe Topper, the founder of CrossAmerica, formerly Lehigh Gas Partners. The interests divested by Couche-Tard, consisting of 100% of the interest in CrossAmerica's General Partner, and all of CrossAmerica's incentive distribution rights and approximately 7.5 million of its limited partner units, were sold to investment funds controlled by Topper for an undisclosed amount. Joe Topper, founder of CrossAmerica, returns as Chairman of the Board of Directors of CrossAmerica's General Partner. The transaction does not involve any capital outlay by CrossAmerica, nor any change in CrossAmerica's capital structure. The asset exchange transaction between CrossAmerica and Couche-Tard, originally announced in December 2018, remains unaffected. CrossAmerica also expects to close in 1Q20 the previously announced asset exchange transaction between the two parties.

06:51 EST Comstock Mining granted approval for mercury remediation plant in Nevada - Comstock Mining received approval for an Engineering Design Change from the Nevada Division of Environmental Protection approving the Mercury Remediation Pilot Test Plant located within Comstock's existing leach pad. During 2019, Comstock Processing LLC, Comstock's wholly-owned subsidiary that owns all of the property, plant, equipment and permits near Virginia City, NV, entered into a definitive agreement with Mercury Clean Up, in collaboration with Oro Industries, for the manufacture and global deployment of mercury remediation systems to reclaim, treat and remediate mercury, and the entrapped precious metals, from soils, waste and tailings. Comstock recently received approval for the EDC from NDEP approving the Mercury Remediation Pilot Test Plant that will be located within Comstock's existing heap leach pad under Comstock's existing Water Pollution Control Permit. The treatment plant will be a zero-discharge, closed-loop system. This NDEP and EPAbased approvals for sampling, analysis, and management of historically-contaminated soils on Comstock properties enables MCU to commence sampling and testing materials over the next two weeks, with the objective of identifying the best target areas for mercury remediation. The Pilot Test Plant will start operating small batches, likely in January, 2020.

06:47 EST Merck: EC approves two new regimens of KEYTRUDA - Merck announced that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1. This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment, demonstrated a significant improvement in overall survival as monotherapy and in combination with chemotherapy, in patients whose tumors expressed PD-L1. This approval allows marketing of the KEYTRUDA monotherapy and combination regimen in all 28 EU member states plus Iceland, Lichtenstein and Norway.

06:38 EST Avery Dennison to acquire Smartrac's RFID Inlay business for EUR225M - Avery Dennison announced a definitive agreement to acquire Smartrac's Transponder (RFID Inlay) Division, for the purchase price of EUR225M, subject to certain closing and post-closing adjustments. The division is a leader in the development and manufacture of RFID products, with 2019 estimated global revenue of approximately EUR125M, or approximately $140M, and approximately 900 employees. The combination creates a platform with over $450M in revenue offering long-term growth and profitability above the company average, with strong research and development capabilities, expanded product lines, and added manufacturing capacity. Smartrac is headquartered in Amsterdam, the Netherlands. The company has manufacturing facilities in Germany, Malaysia, China, and the United States. The acquisition is expected to have an immaterial impact to the company's adjusted earnings per share in 2020. Avery Dennison plans to fund the acquisition with existing cash and credit facilities, and expects the transaction to close in a few months, subject to customary closing conditions and approvals.

06:33 EST ChromaDex: EC votes in favor on Nicotinamide Riboside Chloride as a novel food - ChromaDex announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride as a novel food ingredient at a daily serving of 300mg for the healthy adult population.This approval follows a positive opinion issued by the European Food Safety Authority in August 2019. To date, ChromaDex has invested millions of dollars in safety and human clinical trials on its patent-protected NR (commercially known as Niagen) and has entered research agreements with more than 170 leading research institutions, including Dartmouth, the National Institutes of Health, University of Iowa, and the Scripps Research Institute.

06:16 EST Ideaya Biosciences presents data from IDE196 trial for treatment of MUM - Ideaya Biosciences announced it has presented data from an ongoing Phase 1/2 clinical trial. This clinical trial is evaluating the tolerability and preliminary clinical activity of IDE196 for the treatment of Metastatic Uveal Melanoma, or MUM, and other solid tumors harboring GNAQ or GNA11, or GNAQ/11, mutations activating the PKC signaling pathway. Cohort 1 patients received 300mg BID, and Cohort 2 patients received 200mg BID for the first 7-days and then 400mg BID for all subsequent doses. Run-in dosing schema utilized in Cohort 2 with objective to enhance exposure and improve tolerability. Overall, 27 total patients enrolled in the Phase 1 dose escalation portion including:12 patients in the two MUM DLT cohorts,14 patients in a MUM overflow cohort and one cutaneous melanoma patient having a tumor with a GNA11 mutation in a non-MUM GNAQ/11 cohort. All 12 patients in the two DLT cohorts remained on therapy with duration of treatment ranging from 1.3 to 4.0 months. No dose limiting toxicities were reported in the two MUM DLT cohorts; no adverse events greater than Grade 3 and no patient discontinuations due to AEs were reported in any patients. Additional Phase 1 patients enrolled in this ongoing trial post-October 28 to better characterize tolerability and pharmacokinetics for Phase 2 dose selection. On-track for Phase 2 dose-selection and expansion into the potential registration-enabling portion of the trial for MUM in December. Interim data with efficacy for GNAQ/11 Phase 1/2 basket trial expected in Q2/Q3 2020.

06:09 EST JAKKS Pacific names John Kimble as CFO, extends CEO Berman's contract one year - JAKKS Pacific (JAKK) announced the appointment of John Kimble as Executive Vice President and CFO, effective November 20. Kimble worked for over 12 years in various VP / leadership positions at The Walt Disney Company (DIS) covering Finance, Strategy, Operations, and Business Development. More recently, Kimble spent six years at Mattel (MAT) where he held several positions, including Vice President & Head of Corporate Development, Licensing Acquisitions, M&A. The company also announced that the term of CEO Stephen Berman's employment has been extended for one year through December 31, 2021.

06:07 EST Lowe's announces restructuring of Canadian operations - Lowe's reported net earnings of $1B and diluted EPS of $1.36 for the quarter ended Nov. 1, which included non-cash pre-tax charges of $53M. The $53M non-cash pre-tax charges referenced above resulted from the company initiating a strategic review of its Canadian operations during the third quarter. This review led to long-lived asset impairments and a change to the Canadian leadership team in the third quarter. Based on the findings of the strategic review, in the fourth quarter, the company decided to take the following actions to improve future sales performance and profitability: Close 34 underperforming stores in Canada; Undertake a process to simplify multiple Canadian store banners to drive efficiency and reduce operational complexity; Reorganize the corporate support structure across Canada to more efficiently serve stores; and Rationalize the product assortment across the simplified Canadian store banners, to present a more coordinated assortment to the customer.

06:03 EST LivaNova restructures heart valve business line, ends valve replacement program - LivaNova is ending its Caisson Transcatheter Mitral Valve Replacement program and will undertake a restructuring of its heart valve business to improve profitability and ensure business continuity. The LivaNova heart valve business line represented nearly $130M in revenue for full-year 2018 and has experienced a revenue decline over the last five years across both biological and mechanical valves. These declines were due to multiple market conditions, while portfolio maintenance costs increased specifically due to higher regulatory requirements. Under this plan, LivaNova's Saluggia, Italy facility will become dedicated to R&D and production of mechanical heart valves, rings, accessories and Nitinol stents. LivaNova tissue heart valve production will be concentrated in the company's Vancouver, Canada plant. The closure of Caisson TMVR operations in Minneapolis, Minn. will be effective at the end of 2019. Under the restructuring plan, it is expected that approximately 150 employees can be potentially impacted in the three sites of Saluggia, Vancouver and Minneapolis.

05:54 EST KBR awarded Hydrochloric Acid Purification contract from Italmatch - KBR announced it has been awarded a contract for its PLINKE Hydrochloric Acid Purification technologies by Italmatch Deutschland GmbH for its phosphorous acid production plant in Frankfurt, Germany. Under the terms of the contract, KBR will provide technology license, basic and detailed engineering, proprietary equipment and related advisory services to Italmatch to help with the production of phosphorous acid as well as absorption and recovery of hydrochloric acid.

05:23 EST Vertex says CEPS approved national reimbursement of ORKAMBI - Vertex Pharmaceuticals announced that the French Authorities (Comite economique des produits de sante, or CEPS) have approved national reimbursement of ORKAMBI for people ages two and older with cystic fibrosis, or CF, who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. ORKAMBI will be available for all eligible patients once the agreement has been published in the French Official Journal.

05:21 EST Vertex

05:16 EST NetApp, Google Cloud advance strategic partnership - NetApp (NTAP) and Google Cloud (GOOG, GOOGL) announced the general availability of NetApp Cloud Volumes Service, NetApp Cloud Volumes ONTAP for Google Cloud, and support for Anthos on NetApp HCI to help organizations focus on innovation across any hybrid environments. "As enterprises seek to take advantage of the agility and efficiency benefits of the cloud, they need to know that their data is secure and in the right place, for the right cost, at scale. To achieve these goals, they are building data fabrics that provide maximum flexibility as they move to hybrid multicloud environments. With NetApp and Google Cloud, customers can unlock the power of their data with tightly integrated, enterprise-class data solutions that are optimized and validated for Google Cloud."